What’s more, researchers estimate that in almost 50% of cases the genomic changes identified could provide oncologists with additional information useful for their patients, such as which ones could be considered for clinical trials.
A second phase (AURORA 2.0) will focus on specific subtypes of metastatic breast cancer, namely invasive lobular cancer, triple negative breast cancer, and those with late relapses, 10 or more years after their primary diagnosis. BIG considers these as areas of high unmet need, for which AURORA could provide high scientific and clinical impact.